IMPROVED EXPRESSION OF HUMAN MULTIDRUG RESISTANCE GENES AND IMPROVED SELECTION OF CELLS TRANSDUCED WITH SUCH GENES

Abstract: A DNA sequence for a human m &cir& _d &cir& _r &cir& _l &cir& _ gene, which encodes p-glycoprotein, wherein at least one base in a splice region of the DNA encoding p-glycoprotein is changed. Such a mutation prevents truncation of the p-glycoprotein upon expression thereof. There is also provided a method of identifying cells which express the human m &cir& _d &cir& _r &cir& _l &cir& _ gene in a cell population that has been transduced with an expression vehicle including a human m &cir& _d &cir& _r &cir& _l &cir& _ gene. The method comprises contacting the cell population with a staining material, such as rhodamine 123, and identifying cells which express the human m &cir& _d &cir& _r &cir& _l &cir& _ gene based on differentiation in color among the cells of the cell population. This method has allowed identification of retroviral producer clones facilitate m &cir& _d &cir& _r &cir& _ gene transfer into primary cells. Repopulating hematopoietic stem cells have been genetically engineered with the human m &cir& _d &cir& _r &cir& _l &cir& _ gene.

Description: IMPROVED EXPRESSION OF HUMAN MULTIDRUG RESISTANCE GENES AND IMPROVED SELECTION OF CELLS TRANSDUCED WITH SUCH GENES This invention relates to the transduction of cells with human multidrug resistance (mdr) genes and the expression thereof, as well as the selection or identification of cells transduced with such genes. More particularly, this invention relates to the enhanced expression of mdr genes by transduced cells, and an improved method of selecting or identifying cells transduced with mdr genes. Genes for multidrug resistance such as, for example, mdrl and mutated forms thereof, encode proteins of a class known as p-glycoprotein, that confer resistance to a range of cytotoxic drugs used in the treatment of human malignancies. The introduction and expression of the mdrl gene in human cells may serve several useful purposes in the treatment of diseases. For example, the mdrl gene can function as a dominant selectable marker that will allow for positive selection of cells transduced by an expression vehicle, such as, for example, a retroviral vector, ex vivo or in vivo. Used in this manner, expression of the mdrl ene in normal human cells may be useful in increasing the proportion of a target cell population that has been transformed by an expression vehicle, such as a retroviral particle. Also, expression of the mdrl gene in normal human cells may permit more intensive use of chemotherapeutic drugs in the treatment of cancer. For example, expression of the mdrl gene in human bone marrow cells could reduce the severity and duration of cytopenias following chemotherapy, which may facilitate dose intensification while reducing morbidity and mortality. In accordance with an aspect of the present invention, ther is provided human mdrl DNA or RNA which encodes p-glycoprotein o an analogue or fragment of such DNA or RNA which encodes an iso-form of p-glycoprotein which confers multidrug resistance. The DNA or RNA includes at least one splice site, and at least one base in the splice site has been changed to a different base which thereby inactivates the splice site. Preferably, the DNA or RNA is a DNA or RNA sequence for human mdrl which encodes p-glycoprotein wherein at least one base in a splice site of sai DNA encoding p-glycoprotein is changed. The natural human mdrl gene contains at least one functiona splice donor site and splice acceptor site. This invention provides a modification of the mdrl gene whereby at least one base in a splice site has been changed to a different base which thereby inactivates the splice site. The term "human mdrl gene" as used herein means the wild type human mdrl gene, which encodes p-glycoprotein, as well as mutated human mdrl genes which encode what are known as iso-form of p-glycoprotein. Such mutated genes include a mutation in which the human mdrl DNA encodes a p-glycoprotein in which the first 23 amino acids at the N-terminal are deleted (Currier, et al., J. Biol. Chem., Vol. 264, pgs. 14376-14381 (1989)); insertional mutation(s) in the human mdrl DNA in which amino acids have been inserted into ATP binding or utilization sites (Currier, et al; 1989); a complementary human mdrl DNA sequence (cDNA sequence) in which codon 185, which encodes Gly 185, has been changed from GGT to GTT to encode Val 185. (PCT Applicatio No. W087/05943; Choi, et al., Cell, Vol. 53, pgs. 519-529 (1988) Safa, et al., Proc.Nat.Acad.Sci. , Vol. 87, pgs. 7225-7229 (1990)); and a chimer; . gene encoding a protein having adenosin deaminase added to the N-terminal of p-glycoprotein (Germann, e al., J. Biol. Chem., Vol. 264, pgs. 7418-7424 (1989)). Although the scope of this aspect of the present invention is not to be limited to any theoretical reasoning, Applicants have found that aberrant splicing of the mdrl gene may occur within the coding sequence for p-glycoprotein. Such splicing, which uses cryptic sp , ice donor and splice acceptor sites, results in the production of expression vehicles (such as, for example, recombinant retroviruses) that contain a truncated mdr gene, which encodes a truncated and non-functional p-glycoprotein. Applicants have found a cryptic splice donor site having a length of 9 bases from nucleotide 760 to nucleotide 768 of the human mdrl gene, and which has the following sequence: CAGGTATGC A cryptic splice acceptor site was also found, which has a leng of 16 bases from nucle tide 2729 to nucleotide 2744 of the huma mdrl gene; and which has the following sequence: ACATTTTTCCTTCAGG Applicants have found that, by changing at least one base of th cryptic splice donor and/or acceptor sites, one may suppress aberrant splicing of the mdrl gene and maximize the transfer of DNA encoding functional p-glycoprotein into desired cells. In one embodiment, the at least one base which is changed in a splice donor site. In another embodiment, the at least on base which is changed is in a splice acceptor site. In yet another embodiment, at least one base is changed in a splice donor site and at least one base is changed in a splice accepto site. In a preferred embodiment, the at least one base in a spli site which is changed is in the splice donor site and is at lea one of guanine (G) or thymine (T) contained in the splice donor site wherein G and T are adjacent. In another preferred embodiment, the at least one base in a splice site which is changed is in the splice acceptor site and is at least one of adenine (A) or guanine (G) contained in the splice acceptor site wherein A and G are adjacent. In a more preferred embodiment, at least one base is changed in the splice donor site wherein the at least one base is at least one of G or T contained in the splice donor site wherein G and T are adjacent; and at least one base is changed in the splice acceptor site wherein the at least one base is at least one of A or G contained in the splice acceptor site wherein A an G are adjacent. In another embodiment, the at least one base in a splice site is changed such that a codon encoding an amino acid is changed to a different codon encoding the same amino acid. Preferably, the at least one base is the third, or "wobble" base in the codon. In one embodiment, codon 139, located in the splice donor site, and which encodes Arg, is changed from AGG to AGA, which also encodes Arg. In another embodiment, codon 733, located in the splice acceptor site, and which encodes Gin, is changed from CAG to CAA, which also encodes Gin. It is also contemplated that in yet another embodiment, both codon 139 of the mdrl gene is changed from AGG to AGA, and codon 733 of the mdrl gene is changed from CAG to CAA. In one embodiment, the DNA sequence is further mutated such that at least a portion of the 5' untranslated region of the DNA has been removed. In another embodiment, the DNA sequence may be further mutated such that at least a portion of the 3' untranslated region of the DNA has been removed. In yet another embodiment, the DNA sequence is further mutated such that at least a portion of the 5' untranslated region of the DNA and at least a portion of the 3' untranslated region of the DNA have been removed. Although Applicants do not intend to be limited thereby, the DNA of the human mdrl gene is quite large and contains extended 5' and 3' untranslated regions. Such extended regions may result i the generation of a reduced titer of viral vector particles, suc as retroviral vector particles, which may be engineered with suc DNA. Thus, removal of at least a portion(s) of the 5' and/or 3' untranslated regions may enable one to insert such DNA into a viral vector, such as a retroviral vector, whereby one generates an increased titer of retroviral particles. Within the scope of the present invention, up to the entire 5' untranslated region and/or up to the entire 3* untranslated region may be removed. In accordance with another aspect of the present invention, there is provided DNA (or RNA) encoding a protein which provides for multidrug resistance, wherein the DNA includes the following sequence: CAGGTATGC At least one base is changed to a different base. Preferably at least one base of the GT doublet is changed. In accordance with yet another aspect of the present invention, there is provided DNA (or RNA) encoding a protein which provides for multidrug resistance, wherein the DNA include the following sequence: ACATTTTTCCTTCAGG At least one base is changed to a different base. Preferably, a least one base of the AG doublet is changed. In one embodiment, the DNA encoding a protein which provide for multidrug resistance includes a first sequence. CAGGTATGC, and a second sequence: ACATTTTTCCTTCAGG At least one base in the first sequence, and at least one base i the second sequence is changed to a different base. Preferably, at least one base of the GT doublet of the first sequence is -β- changed, and at least one base of the AG doublet of the second sequence is changed. The changed DNA or RNA sequence for a human mdrl gene, or the changed DNA or RNA encoding a protein which provides for multidrug resistance, of the present invention may be cloned int any of a variety of expression vectors by genetic engineering techniques known to those skilled in the art. Such expression vectors include, but are not limited to, prokaryotic vectors, including bacterial vectors; eukaryotic vectors, such as, for example, yeast vectors and fungal vectors, and viral vectors, such as, but not limited to, retroviral vectors, and non-retroviral vectors such as, but not limited to, adenoviral vectors, adeno-associated viral vectors, and Herpes virus vectors. In one embodiment, the changed DNA (or RNA) is cloned into a retroviral expression vector. It is also contemplated that the changed DNA or RNA may be introduced into cells by mean of non-viral systems and non-plas id-based systems. Such system include, but are not limited to, the injection of the naked changed DNA or RNA into a desired cell, liposomes which encapsulate such DNA or RNA, and which deliver such DNA or RNA t a cell, and the- coupling of the DNA or RNA to a protein or other agent which binds to a cellular receptor. Retroviral vectors which may be employed include those derived from Moloney Murine Leukemia Virus, Moloney Murine Sarcoma Virus, Rous Sarcoma Virus, Harvey Sarcoma Virus, and Spleen Necrosis Virus. In one embodiment, the retroviral vector may be derived from Moloney Murine Leukemia Virus and is one of the LN series of vectors, as described in Miller, et al., Biotechniques, Vol. 7, pgs. 980-990 (1989). Such vectors have a portion of the packaging signal derived from a mouse sarcoma virus, and a mutated gag initiation codon. In another embodiment, the retroviral vector may include at least four cloning, or restriction enzyme recognition sites, wherein at least two of the sites have an average frequency of appearance in eukaryotic genes of less than once in 10,000 base pairs; i.e., the restriction product has an average DNA size of at least 10,000 base pairs. Preferred cloning sites are selecte from the group consisting of NotI, SnaBI, Sail, and Xhol. In a preferred embodiment, the retroviral vector includes each of these cloning sites. When a retroviral vector including such cloning sites is employed, there may also be provided a shuttle cloning vector which includes at least two cloning sites which are compatible with at least two cloning sites selected from the group consisting of NotI, SnaBI, Sail, and Xhol located on the retroviral vector. The shuttle cloning vector also includes at least one desired gene which is capable of being transferred fro the shuttle cloning vector to the retroviral vector. The shuttle cloning vector may be constructed from a basic "backbone" vector or fragment to which are ligated one or more linkers which include cloning or restriction enzyme recognition sites. Included in the cloning sites are the compatible, or complementary cloning sites hereinabove described. Genes and/or promoters having ends corresponding to the restriction sites of the shuttle vector may be ligated into the shuttle vector throug techniques known in the art. The shuttle cloning vector can be employed to amplify DNA sequences in prokaryotic systems. The shuttle cloning vector ma be prepared from plasmids generally used in prokaryotic systems and in particular in bacteria. Thus, for example, the shuttle cloning vector may be derived from plasmids such as pBR322; pUC 18; etc. Examples of retroviral vectors having at least two restriction enzyme recognition sites having an average frequency of appearance in eukaryotic genes of less than once in 10,000 base pairs, and of the shuttle cloning vectors employed in transfering genes to such vectors are further described in PCT Application No. W091/10728. The vectors also include one more more promoters. Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller, et al., Biotechniques, Vol. 7, No. 9, pgs. 980-990 (1989), or any other promoter (e.g., cellular promoter such as eukaryotic cellular promoters including, but not limited to, the histone, pol III, and β-actin promoters). Other viral promoters which may be employed include, but are not limited to, adenovirus promoters, TK promoters, and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein. The vector may also further include a heterologous or foreign gene. Heterologous or foreign genes which may be placed into the vectors of the present invention include, but are not limited to genes which encode cytokines or cellular growth factors, such as ly phokines, which are growth factors for lymphocytes. Other examples of foreign genes include, but are not limited to, genes encoding soluble CD4, Factor VIII, Factor IX, ADA, the LDL receptor, Apol, tumor necrosis factors (TNF's) and ApoC. Suitable promoters which may control the foreign genes include those hereinabove described. The vector including the DNA of the present invention may be transduced into a suitable packaging cell line. Examples of suitable packaging cell lines include the PA317 cell line and the PE501 cell line (Miller, et al., 1989), and the PAT 2.4 cell line (U.S. application Serial No. 792,281, filed November 14, 1991.) Transduction of the packaging cell line may be accomplished by standard techniques such as electroporation or CaP0 4 precipitation. Vector particles generated from such producer cells may then be employed to generate a producer cell line, and to transduce cells (eg., eukaryotic cells such as mammalian cells), which may be administered to a host as part of a gene therapy procedure. Examples of cells which may be transduced include, but are not limited to, primary human cells such as primary human nucleated blood cells (such as leukocytes, and lymphocytes such as TIL cells, T-lymphocytes, and β-lymphocytes) tumor cells, endothelial cells, epithelial cells, keratinocytes, stem cells, bone marrow cells, hepatocytes, connective tissue cells, fibroblasts, mesenchymal cells, mesothelial cells, and parenchymal cells. Upon transfection or transduction of a packaging cell line with a retroviral vector, it is essential that the producer cell line generate a sufficient titer of vector particles for gene therapy protocols. Selection for growth of such packaging or producer cells in the presence of colchicine has resulted in the isolation of producer clones with viral titers below what is currently adequate for clinical gene therapy protocols. It is therefore another object of the present invention to provide a method of selecting producer cells which generate an acceptable titer of retroviral particles including a human mdrl gene, and in particular for generating an adequate titer of retroviral' particles suitable for inserting and expressing the mdrl gene in primate cells, particularly in primate repopulating hematopoietic stem cells. In accordance with an aspect of the present invention, ther is provided a method of identifying cells which overexpress a gene encoding multidrug resistance (preferably such gene is the human mdrl gene) in a cell population transduced with an expression vehicle including a gene which encodes a protein whic provides for multidrug resistance (preferably such gene is the human mdrl gene). The method comprises contacting the cell population with a staining material, and identifying the cells which overexpress the gene encoding a protein which provides for multidrug resistance (preferably the human mdrl gene) based on differentiation of color among the cells of the cell population. Such differentiation in color may be based on differences in color intensity between cells which overexpress the human mdrl gene and cells which do not overexpress the human mdrl gene (for example, cells which contain vectors including the human mdrl gene, whereby such cells overexpress the human mdrl gene, may be brighter or duller than those cells which do not contain vectors including the human mdrl gene, whereby such cells which express the human mdrl gene at normal levels or do not express the gene); or differences in color or shades of color between cells which contain vectors including the human mdrl gene, and thereby overexpress the human mdrl gene, and cells which do not contain vectors including the human mdrl gene, and thereby express the human mdrl gene at normal levels or do not express the human mdr gene. Alternatively, cells which contain vectors including the human mdrl gene, and thereby overexpress the human mdrl gene may change color after staining, while cells which do not contain vectors which include the human mdrl gene do not change color after staining. The term "overexpress" as used herein, means that the gene encoding multidrug resistance is expressed at a level above that which is expressed by a normal human cell. In normal human cells, the mdrl gene is expressed at low levels or is not expressed. In cells transduced with an expression vehcile including the mdrl gene, the expression level of the mdrl gene i considerably increased, and thus, the mdrl gene is "overexpressed. " Applicants have found that, by identifying cells which overexpress the human mdrl gene in a cell population transduced with infectious viral particles which include the human mdrl gene, in accordance with the method of the present invention, Applicants have been able to isolate clones which produce higher viral titerε than clones selected with drugs such as colchicine, for example. In one embodiment, the staining material is a fluorescent dye. Fluorescent dyes which may be employed include, but are no limited to, rhodamine 123, 3,3'-diethylo « ;acarbocyanine iodide (DiOC,), and 3,3'-diethyloxadicarbocyanine iodide (DODC iodide). In one embodiment, the fluorescent dye is rhodamine 123. Rhodamine 123 ordinarily concentrates within the mitochondria of cells, but can be effluxed from the cell by p-glycoprotein. Cells stained with rhodamine 123 that do not express p-glycoprotein or express p-glycoprotein at normal or lower than normal levels appear "bright" by fluorescence microscopy or by FACS analysis, whereas cells that overexpress p-glycoprotein appear "dull," even if small quantities of p-glycoprotein are expressed. (Chaudhary, et al., Cell, Vol. 66, pgs. 85-94 (July 12, 1991)). Thus, producer cells or other cells which have incorporated and express a functional human mdrl gene may be distinguished from non-transformed cells on the basis of this "dull" staining phenotype. Such a method may also be employed to determine viral titer of human mdrl retrovirus producer cell lines. In one embodiment a defined number of target cells are exposed to serial dilutions of a viral supernatant produced by a defined number of producer cells. After infection (eg., at about 48 hrs. after infection), the cells are stained with rhodamine 123 and allowed to efflux the dye. The proportion of "dull" cells can be visually estimated by fluorescence microscopy, or accurately quantitated by scoring a defined number of individual cells by FACS analysis Because the proportion of cells overexpressing p-glycoprotein is known, it is possible to calculate accurately the minimum number of infectious viral particles present in a known volume of viral supernatant. Although it has been demonstrated that retroviral vectors may be used to transfer and express the mdrl gene in cultured cells (Proc.ΪJat.Acad.Sci., Vol. 85, pgs. 1595-1596 (1988)); in murine repopulating hematopoietic stem cells (Sorrentino, et al. Science, (in press)), and in murine hematopoietic progenitors in vitro (McLachlin, et al., J.Nat.Cane.Inst. , Vol. 82, pgs. 1260-1263 (1990)), there has been no demonstration of transfer and expression of the mdrl gene in primate cells, and in particular in primate stem cells capable of reconstituting transplant recipients. Thus, in accordance with an aspect of the present inventio there is provided a primate cell which is genetically engineere with DNA (RNA) which encodes a protein which provides multidrug resistance. The DNA (RNA) may be any DNA (RNA) which encodes a protein which provides multidrug reistance or the changed DNA o RNA sequences which are hereinabove described. Applicants have discovered that by selecting for cells transduced with a gene encoding multidrug resistance in accordance with the selection method hereinabove described, one is able to obtain producer cells which generate a sufficient titer of infectious viral particles which provide for the transfer and expression of multidrug resistance genes in primat cells, in particular in primate repopulating hematopoietic stem cells. Primate cells which may be genetically engineered with suc DNA (RNA) include, but are not limited to, primate bone marrow cells, preferably enriched primate bone marrow cells, and hematopoietic progenitor (CD34+) cells or hematopoietic stem cells (in particular, primate repopulating hematopoietic stem cells), and human primary cells. The hematopoietic stem cells w low may also be CD33 and HLA-DR . (Chaudhary, et al., 1991) Th primate cells may be obtained from humans or other primates, su as monkeys, for example. This aspect of the present invention is particularly applicable to the use of primate repopulating hematopoietic ste cells which are genetically engineered with DNA (RNA) which encodes a protein which provides multidrug resistance. Such st cells give rise to bone marrow cells and may be administered, f example, to a patient who has undergone chemotherapy and/or radiation treatment in order to regenerate healthy bone marrow cells in the patient. Thus Applicants have devised a system for identifying producer cells which generate a sufficient titer of viral particles including a gene encoding multidrug resistance, whereby such viral particles may be used to infect primate repopulating hematopoietic stem cells, which may then be administered to a patient in order to regenerate bone marrow in said patient, wherein such regenerated bone marrow is resistant to the toxic effects of chemotherapy. In one embodiment, bone marrow cells are harvested by needl aspiration from a primate, and purified by positive selection fo cells expressing the CD34 antigen. CD34 selected cells are enriched 50-100 fold in clonogenic hematopoietic progenitors and contain all of the repopulating stem cells. Alternatively, the bone marrow cells may be purified in accordance with the procedures described in U.S. Patent No. 5,061,620. The CD34+ cells are incubated in vitro in the presence of stimulatory hematopoietic growth factors and in the presence of retroviral supernatant containing infectious viral particles which include a multidrug resistance gene. The viral particles are generated from a producer cell line selected in accordance with the selection procedure hereinabove described. After incubation, the cells are transplanted into recipients suitably treated to receive a bone marrow transplant. After transplantation, bone marrow cells, peripheral blood leukocytes, purified granulocytes, and T-lymphocytes are assayed for presenc and expression of the introduced mdrl gene. The invention will be described with respect to the following examples; however, the scope of the present invention is not intended to be limited thereby. EXAMPLE 1 A. Construction of plasmid pG1. Plasmid pGl was constructed from pLNSX (Palmer et al., Blood, 73:438-445; 1989). The construction strategy for plasmid pCl is shown in Figure 1. The 1.6 kb EcoRI fragment, containing the 5' Moloney Sarcoma Virus (MoMuSV) LTR, and the 3.0 kb EcoRI/Clal fragment, containing the 3' LTR, the bacterial origin of replication and the ampicillin resistance gene, were isolate separately. A linker containing seven unique cloning sites was then used to close the EcoRI/Clal fragment on itself, thus generating the plasmid pGO. The plasmid pGO was used to generat the vector plasmid pGl by the insertion of the 1.6 kb EcoRI fragment containing the 5' LTR into the unique EcoRI site of pGO. Thus, pGl (Figure 3) consists of a retroviral vector backbone composed of a 5' portion dervied from MoMuSV, a short portion of gag in which the authentic ATG start codon has been mutated to TAG (Bender et al. 1987), a 54 base pair multiple cloning site (MCS) containing from 5 1 to 3' the sites EcoRI, NotI, SnaBI, Sail, BamHl, Xhol, Hindlll, Apal, and Clal, and a 3' portion of MoMuLV from base pairs 7764 to 7813 numbered as described in (Va Beveren et al., Cold Spring Harbor, Vol. 2, pg. 567, 1985). (Figure 2). The MCS was designed to generate a maximum number o unique insertion sites, based on a screen of non-cutting restriction enzymes of the pGl plasmid, the neo gene, the o β-galactosidase gene, the hygromycin gene, and the SV40 promoter. B. Construction of pGlMDl. pMDR2000 (Ueda, et al. , PNAS. Vol. 84, pgs. 3004-3008 (May 1987)), which contains an mdrl cDNA sequence (Figure 4) describe in PCT application number W087/05943, wherein the first 282bp of the untranslated 5' region and the last 23bp of the untranslated 3* region of the cDNA sequence have been removed, was cut with Sad and EcoRI, and was inserted into a multiple cloning site of Sad and EcoRI digested pGEM2 (Figure 5.) (Promega, Madison, WI) to form pGEM2MDR. pGEM2MDR was then cut with S al at the 5' end of the multiple cloning site and a SacII linker having a length of 8bp was inserted. At the 3' end of the plasmid, the plasmid was cut with EcoRI and a 12bp Xhol linker was inserted. The resulting plasmid was pMDR2000XS. (Figure 6.) Plasmid pMDR2000XS was then cut at the 5' end of the cDNA sequence for mdrl with Hhal, and at the 3' end of the cDNA sequence for mdrl with Haell, and a 3,845bp fragment was removed Such cutting removed an additional 131 bp from the 5' end, and a additional 384 bp from the 3' end of the cDNA. A linker was the added to the 3' sequence to reconstitute the amino acids that were cut off by cutting with Haell and to add the TGA stop (or termination) codon back into the sequence. The linker has four restriction enzyme sites, Hpal, Xhol, Bglll, and Clal, and has the following sequence: 5'-A G T G A A C T C T G G T T A A C T C C 10 20 A C T C G A G C A C A G A T C T G G A 30 C A T C G A T A C T C 40 50 Bases 12-17 are recognized by Hpal, bases 22-27 are recognized by Xhol, bases 31-36 are recognized by Bglll, and bases 41-46 are recognized by Clal. pGl was then cut with SnaBI and Clal, and the mdrl fragment containing the added linker was cut with Clal and inserted into the SnaBI and Clal digested pGl to form pGlMDl (Figure 7.) C- Changing codons 139,185, and 733 of the mdrl gene. Changing the mdrl gene in pGlMDl such that codon 139 is changed from AGG to AGA, codon 185 is changed from GTT to GGT (whereby Val is changed to Gly in the resulting expressed p-glycoprotein), and codon 733 is changed from CAG to CAA may be accomplished by either of the following strategies. 1. Introduction of point mutations into G1MD1 by site-directed mutagenesis. pGlMDl is digested with NotI and Xhol, and a NotI-Xhol fragment is cloned into the phagemid pBluescriptSK*(Stratagene) . The resulting subclone is transformed into E. coli strain CJ236 (Biorad). A 5ml culture is grown at 37°C overnight in LB broth - - with 200μg/ml ampicillin and 30μg/ml chloramphenicol. 2.5ml of this culture is then added to 25 ml of fresh media with the same antibiotics, and grown at 37°C until the 0.D.600 of the culture reaches 0.3. Helper phage R408 (Stratagene) is then added at a multiplicity of infection of 20 to the culture. The culture is then incubated by vigorous shaking for 8 hours. The culture is then harvested by centrifugation at 17,000xg for 15 minutes at 4°C. The supernatant fluid is harvested and spun again at 17,000xg for 15 minutes at 4°C. The supernatant is then harvested and measured for volume. A 1/4 volume of a solution containing 3.5 M ammonium acetat and 20% polyethylene glycol is then added to the supernatant to precipitate the phage. The solution and supernatant mixture is incubated at room temperature for 15 minutes. The precipitate i then centrifuged at ll,000xg for 15 minutes at 4 β C. The resulting pellet is suspended in 400μlTE (lOmM Tris, ImM EDTA) and extracted with phenol/chloroform until the interphase is clear. The DNA (phage/template) is then ethanol precipitated by standard procedures. 2ng of the following antisense oligonucleotides: (a)5'-T C T G T. A C T G G T C T A T A C G G A T A A T 10 20 A A T G T C - 3' 30 , wherein the TCT sequence (nucleotides 11-13) will provide for a change of codon 139 from AGG to AGA; (b)5'-C T A A T T A C T T C C A T A A C C A C T G T T 10 20 T T A A C C - 3' 30 , wherein the CCA sequence (nucleotides 11-13) will provide for a change of codon 185 from GTT to GGT (whereby Val 185 is changed to Gly 185); and (c)5' - G T A A A A A G G A A G T T C C A A A G T G T A 10 20 A A C C G T - 3 ' 30 , wherein the GTT sequence (nucleotides 12-14) will provide for a change of codon 733 from CAG to CAA, and 200ng of the phage/template DNA are then mixed in lOμl of TE The mixture is heated to 70°C, and then allowed to cool slowly t room temperature in order to anneal the oligonucleotides to the template. Deoxynucleotide triphosphates are then added to the mixture, followed by T4 DNA polymerase, T4 ligase, 10X synthesis buffer, and water to make the volume 20μl. The mixture is then placed on ice for 5 minutes, then at 25°C for 5 minutes, and the at 37°C for 90 minutes. At the end of the 90 minute incubation, 90μl of TE is added and 5μl of the resulting mixture is used to transform E. coli strain DH5α. Mutagenized clones are then identified by colony hybridization with the oligonucleotides (a), (b), and (c) hereinabove described. The identified and changed mdrl gene is then cut out of pBluescript with NotI and Xhol and cloned into pGl cut with NotI and Xhol to form pGlMD3. 2. Introduction of Point Mutations into G1MD1 by PCR Based Strategy The cryptic splice donor site and the Gly to Val point mutation in codon 185 are contained within a NotI to Apal restriction fragment of pGlMDl. This NotI to Apal fragment can be excised, purified, and subcloned into a pUC based cloning vector called pUC007 (Sorrentino, et al., Nucleic Acids Research Vol. 18, No. 9, pgs. 2721-2731 (1990)) that contains a synthetic polylinker multiple cloning site. The vector is prepared by partial digestion of pUC007 with Fspl, and complete digestion with Apal. The insert is prepared by digesting with NotI, blunting the NotI digested end with Klenow, and then digesting with Apal. Following ligation, the abutment of the blunt Fspl site with the blunted NotI site will recreate a NotI site that can be used to excise a NotI to Apal fragment. Fo11owing subcloning of the NotI to Apal fragment into pUC007 (to form pMDINA), the cryptic splice donor site and the codon 185 point mutation will be contained within a unique BstXI to MscI fragment. A strategy of overlapping or "recombinant" P to introduce point mutations into this BstXI to MscI fragment is employed. (Higuchi, PCR Protocols: A Guide to Methods and Applications, Innis, et al., eds, San Diego, Academic Press, pgs 177-183 (1990)). Three sets of PCR primers are made. One set o complementary primers (SD-A and SD-B), which have the following sequences: SD-A:GGAAGACATGACCAGATATGCCTATTATTACAG SD-B:CTGTAATAATAGGCATATCTGGTCATGTCTTCC are centered around the cryptic splice donor site, and differ from the sequence of GlMDl at only one base, located in codon 13 of the mdrl gene, wherein AGG is changed to AGA. This differenc inactivates the splice donor site, although the amino acid is no changed. The second set of primers (C185-A and C185-B), which have the following sequences: C185-A:CTCTAAGATTAATGAAGGTATTGGTGACAAAATTG C185-B:CAATTTTGTCACCAATACCTTCATTAATCTTAGAG are centered at the codon 185 mutation of the mdrl gene and will differ from the sequence of GlMDl only at the point mutation wherein codon 185 is changed from GTT to GGT. This difference corrects the point mutation in the cDNA sequence (Figure 7) and encodes Gly in the final construction. The third set of primers flank the BstXI and MscI restriction sites. These primers (5'Bs and 3'Msc), which have the following sequences: 5'Bst:ATCGCGGATCCATGGTGGTGGGAACTTTGGC 3'Msc:CATCCGGAATTCAGCTGACAGTCCAAGAACAGGACTGATG overlap the BstXI and MscI sites, respectively, and also incorporate another flanking restriction site that will allow th PCR fragment to be conveniently subcloned. Using the technique of "recombinant" PCR, three separate PCR reactions will be initiated, using MD1NA as the template DNA. In these reactions, a "proofreading" thermostable DNA polymerase, such as Vent polymerase marketed by New England BioLabs, is used to avoid misincorporation of nucleotides, as can occur with high frequenc when Taq polymerase is used. In the first PCR reaction, the two primers are 5'Bst and SD-B, and amplify the sequence from the BstXI site to the cryptic splice donor site. In the second PCR reaction, the two primers are SD-A and C185-B, and amplify the sequence from the splice donor to the codon 185 mutation. In th third PCR reaction, the primers are C185-A and 3'Msc, and amplif the sequence from the codon 185 mutation to the MscI site. Following ten cycles of amplification, the product of these thre reactions is purified away from unused primers, nucleotides, and buffer. The purified PCR products are mixed together, and then amplified for an additional 10 to 20 cycles with a "proofreading polymerase such as Vent polymerase, using the 5'Bst and 3'Msc primers. This final PCR reaction results in an amplified PCR product that extends from the BstXI site to the MscI site, and has introduced point mutations into the cryptic splice donor sit and the mutant codon 185. Using the flanking restriction sites, the PCR product is digested with Ba Hl and EcoRI and is subclone into a pUC based vector prepared by digestion with BamHl and EcoRI using inactivation of the l_acZ gene to identify vectors that have incorporated the insert. This construct is referred t as pMDIBM and is used to transform bacteria. Bacteria that contain the plasmid carrying the desired point mutations will be identified by hybridization to allele specific oligonucleotides. MD1BM plasmid DNA isolated from these subclσnes is then sequenced, using standard M13 sequence primers, to confirm that the desired mutations have been introduced, and that no additional mutations have been created. After sequencing, a BstXI to MscI fragment is excised from MD1BM and subcloned into a vector prepared by digestion of MD1NA with BstXI and MscI. This plasmid is referred to as MDINA-C. A NotI to Apal fragment is excised from MDINA-C and inserted into vector prepard by digestion of GlMDl with NotI and Apal. The resulting plasmid is referred to as pGlMDlA, and contains a cDNA for a human mdrl gene that has a conservative point mutation inactivating a cryptic splice donor site, as well as another point mutation that causes a reversion in the amino acid sequence at codon 185 to the wild type sequence. The cryptic splice acceptor site can be corrected using a similar PCR based strategy. A HindiII to Xhol fragment containing the cryptic splice acceptor can be subcloned directly into the HindiII and Xhol sites of pUC007 (This plasmid is designated pMDIHX) . The cryptic splice acceptor is contained within an XmnI to Kpnl fragment. Recombinant PCR is then used to introduce a point mutation into the cryptic splice acceptor site. One primer set is required. The first primer (5'Xmn) having the following sequence: 5'Xmn: ATCGCGGATCCGGAATTATTTCTTTTATTACATTTTTCCTTCAAGGTTTCACATTTGG overlaps the XmnI site and extends past the cryptic splice acceptor. This primer will be identical to the sequence in GlMDl except at one base in codon 733 wherein codon 733 is changed from CAG to CAA, which inactivates the splice acceptor site. The amino acid encoded by codon 733, however, is unchanged. This primer also incorporates a flanking BamHl site to facilitate subcloning of the PCR product. The second primer (3'Kpn), having the following sequence: 3'Kpn: CTCAAAGAGTTTCTGTATGGTACC overlaps the Kpnl site. These primers are used to amplify a fragment of DNA from pMDIHX with a proofreading polymerase such as Vent polymerase. This PCR product is digested with BamHl and Kpnl and subcloned into the BamHl and Kpnl sites of a cloning vector such as pUC19 (This plasmid is designated pMDIXK). This plasmid is used to transform bacteria. Subclones containing the "corrected" sequence are identified by allele specific oligonucleotide hybridization and sequencing as described above. Subsequently, an XmnI to Kpnl fragment from pMDIXK is subcloned into the XmnI and Kpnl sites of pMDIHX (The resulting plasmid is designated pMDIHX-C). Finally, a Hindlll to Xhol fragment from MDIHX-C is subcloned into the HindiII and Xhol sites of pGlMDl t form pGlMDlB, which contains a cDNA for the mdrl gene that has a conservative point mutation inactivating a cryptic splice acceptor site. In order to construct a plasmid that contains a cDNA for an mdrl gene with mutations introduced into the cryptic splice dono site, codon 185, and the cryptic splice acceptor site, a HindiII to Xhol fragment is excised from pGlMDlB. This fragment is then subcloned into a vector prepared by digesting pGlMDlA with HindiII and Xhol. The resulting plasmid is referred to as pGlMDIAB. D. Generation of producer cell lines from PG1MD3 and pGlMDIAB. The vectors pGlMD3 and pGlMDIAB, described in Example 1, which contain the changes in codon 139 (in the splice donor site), in codon 733 (in the splice acceptor site), and in codon 185 (wherein Val 185 is changed to Gly 185), may be placed into packaging cell line to generate vector particles, and to generat producer cell lines. Vector producer cell lines are prepared using established protocols. The packaging cell line PE501 (Miller and Rosman, Biotechniques 7:980-990 (1989)) or cell line GP+E86 is plated at a density of 5 x 10 cells per 100 mm plate and the following da purified vector DNA is introduced using standard CaP0 4 precipitation (Wigler et al. , Cell 14725-731 (1978)). For each plate of cells to be transfected, 20-40 μg of vector DNA is prepared with a co-precipitate consisting of 0.25M CaCl 2 /l mM Hepes (pH 7.2) and 140 mM NaCl, 0.75 mM Na 2 HP0 4 , 25 mM Hepes (pH7.2). The DNA/precipitate is allowed to sit at room temperature for 30 min and then added (1 ml/plate) to the cells in tissue culture medium (DMEM + 10% fetal Bovine serum) for an overnight incubation. The medium is changed to fresh DMEM + serum the following morning. The transfected cells are allowed to grow to near confluence for the next 48 hours, at which point virus supernatant is collected to infect a separate population of PA317 or GP+AM12 vector packaging cell lines at a density of 1 x 10 cells per 100 mm plate seeded 24 hours prior to infection. The standard infection conditions include undiluted virus supernatant, filtered through a 0.2 uM membrane, to which 8 ug/ml polybrene is added. After overnight incubation for 16 hours, the medium is changed to DMEM and 10% Fetal Bovine Serum, and grown until such cells are selected with rhodamine 123. The polyclonal population of GP+Aml2 or PA 317 cells are incubated with rhodamine 123 at a concentration of 1 microgram per ml at 37°C for 30 minutes. Following staining, the cells are allowed to efflux the dye for two hours in medium that did not contain rhodamine. The cells are then trypsinized, and 5 x 10 cells are sorted on a Coulter EPICS Elite FACS machine, with excitation at 480nm and fluorescence measured at 525 nm. The bright cells, which did not express p-glycoprotein, are discarded. Cells that are "dull" following rhodamine staining express p-glycoprotein and are collected for further processing. Example 2 Selection of producer cells generating high titers of viral particles including an mdrl gene. PA317 (amphotropic) packaging cells were transfected by the CaP0 4 method with pGlMDl. 48 hours later, supernatant from the transfected PA317 cells (Miller, et al., 1989) was filtered and added to GP + E86 (ecotropic) packaging cells in the presence of 6 micrograms per ml of polybrene. 24 hours following infection with this transient supernatant, drug selection with colchicine at a concentration of 60 ng/ml was applied. Afte two weeks of drug selection, individual drug resistant GP + E86 clones were isolated and characterized for production of recombinant retrovirus using an RNA slot blot technique (Bodine, et al., Proc. Nat. Acad. Sci., Vol. 87, pgs. 3738-3742 (May 1990)). The ecotropic MDR producer clone with the highest apparent titer, referred to as E4, was used in the subsequent experiments. Filtered viral supernatant from the ecotropic E4 producer cell line was used to infect the amphotropic packaging cell line GP + Aml2 (Markowitz, et al., Virology, Vol. 167, pgs. 400-406 (1988), Markowitz, et al., J. Virol.. , Vol. 62, pgs. 1120-1124 (1988)) In this particular experiment, the GP + Aml2 line was exposed to a total of 6 viral supernatants over the course of on week. Following infection, GP + Aml2 cells that had been transduced with the MDR virus and expressed p-glycoprotein were selected by FACS using rhodamine 123 staining to identify transduced cells. The polyclonal population of GP + Aml2 cells was incubated with rhodamine 123 at a concentration of 1 microgram/ml at 37 degrees C for 30 minutes. Following staining, the cells were allowed to efflux the dye for two hours in medium that did not contain rhodamine. The cells were then trypsinized, and 5 x 10 cells were sorted on a Coulter EPICS Elite FACS machine, with excitation at 480nm and fluorescence measured at 525nm. The bright cells, that did not express p-glycoprotein, were discarded. Cells that were "dull" following rhodamine staining express p-glycoprotein and were collected for further processing. In this particular experiment, the "dull" populatio was further subdivided into three groups ("A", "B", and "C") based on the degree of "dullness." These dull cells were plated at limiting dilution. A total of 1500 wells were plated at two concentrations of one cell per two wells and one cell per five wells. Following two weeks in culture, individual subclones wer expanded and characterized for estimated viral titer using the RNA slot blot technique on filtered viral supernatant. Ten clones were identified with the highest production of packaged and secreted viral RNA. These clones were subsequently characterized for viral titer using the rhodamine titering protocol. In this protocol, 10 ml of media is conditioned by 5 10 producer cells for 24 hours. The supernatant is filtered, and dilutions of the filtered supernatant are used to infect a target cell population, in this case 3T3 cells. To infect 3T3 cells a total of 10 ml of media containing viral supernatant and 6 micrograms per ml of polybrene (or 5 micrograms per ml of protamine sulfate) is added to 10 target cells on a 10 cm plate for a period of 48 to 72 hours. The plate of infected 3T3 cells is then stained with rhodamine 123 at 1 microgram/ml at 37 degrees for 30 minutes, and then destained for two hours in medi without rhodamine. The plate is then trypsinized and analyzed b FACS to quantitate the proportion of cells that express the "dull" phenotype. Alternatively, the plate of cells can be directly examined by fluorescence microscopy. This information is then used to calculate viral titer. For example, if 0.1 ml o viral supernatant is able to confer the "dull" phenotype to 10 percent of 10 cells, then 0.1 ml of viral supernatant contains minimum of lx 10 viral particles, and 1 ml of viral supernatant contains a minimum of 1 x 10 viral particles. As shown in Figure 8A, as the volume of viral supernatant from producer clon GlMDl A1.2 which contacts the 3T3 cells increases from 0.025 ml to 0.1 ml, and then to 1.0 ml, the height of the left peak, whic corresponds to the number of cells having the "dull" phenotype, and which therefore have a lower fluorescence intensity, increases, while there is a decrease in the number of cells having the "bright" phenotype (such cells have a higher fluorescence intensity) as evidenced by the decrease in the size of the right peak. Using this assay, a identified GP + Am clone with a titer of 4 x 10 viral particles per ml was identified. This producer clone was designated GlMDl A1.2. Example._3 PA317 cells (Miller, et al. , 1989), obtained from the ATCC and selected in HMT medium (following the protocol suggested by the ATCC) were transduced with viral supernatant from the ecotropic E4 producer cell line obtained as hereinabove describe in Example 2. The PA317 packaging cell line was serially infected with E4 viral supernatant over the course of 10 days until 100% of the cells in the population expressed the rhodamin "dull" phenotype. The phenotype was evaluated by fluorescence microscopy and FACS analysis on aliquots of the population. A total of 13 exposures to viral supernatants were used. The population of infected PA317 cells were directly plated at limiting dulution. A total of 1,500 wells were plated at dilutions of 1:3 and 1:5 cells per well. Individual clones were isolated and subsequently scored for viral RNA production using the slot blot assay. The subclones with the highest production of viral RNA were then analyzed by the rhodamine titering assay hereinabove described in Example 2. As shown in Figure 8B, as the volume of viral supernatant from producer clone PA15 which contacts the 3T3 cells increases from 0.025 ml to 0.1 ml and the to 1.0 ml, the height of the left peak, which corresponds to the number of cells having the "dull" phenotype, and which therefore have a lower fluorescence intensity, increases, while there is a decrease in the number of cells having the "bright" phenotype (such cells have a higher fluorescence intensity) as evidenced b the decrease in the size of the right peak. One subclone, PA15, was identified which had a titer of 5 x 10 viral particles per ml. Example 4 Bone marrow cells were harvested from the posterior iliac crests and femurs of 3-4 kg juvenile rhesus monkeys (Proc. Natl. Acad. Sci. USA, Vol. 87, pgs. 3738-3742 (1990)). The cells are aspirated into Dulbecco's Modified Eagle's Medium (DMEM) containing 2% fetal calf serum and 10 units of heparin/ml. Five days before the bone marrow harvest, the animals receive 5-fluorouracil (70mg/kg) as a single intravenous bolus. During the bone marrow harvest procedure, the animal receives 100ml of autologous red cells to replace the volume of blood that is removed. Prior to the bone marrow harvest, an in-dwelling central venous catheter is established by standard surgical techniques. After harvest, the bone marrow was diluted with Hank's Buffered Saline Solution (HBSS) and passed through wire mesh to remove clumps of cells. Mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque. Cells expressing the CD34 antigen are isolated by immunoselection (Science, Vol. 242, pgs. 919-922 (1988)) using the magnetic bead g technology. 2-4X10 total bone marrow cells are recovered by th harvest procedure. Approximately 20% of these cells are recovered as the mononuclear cell preparation and 2-3% of these 7 cells are recovered by immunoselection. Thus a total of 2-4X10 CD34 cells are obtained at the time of bone marrow harvest. These were incubated at an initial concentration of 5X10 cells/ml for 36 hours in DMEM, 15% fetal calf serum, penicillin-streptomycin, and 2X glutamine. The following hematopoietic growth factors were added: Stem Cell Factor (lOOng/ml), interleukin-3(50ng/ml) and interleukin-6 (50ng/ml). After 36 hours, the cells were recovered by centrifugation and resuspended at 5X10 cells/ml in fresh medium conditioned by the retroviral producer clone GlMDl A1.2 prepared as described in Example 2. This medium includes hematopoietic growth factors as specified above plus prota ine sulfate at a concentration of 5ug/ml. Every twelve hours the cells were recovered by centrifugation and resuspended in fresh virus conditioned medium with growth factors and protamine. After 72 hours of incubation in the presence of retroviral vector particles, the cells were recovered by centrifugation, resuspended in DMEM or HBSS containing 2% fetal calf serum and 10 units of heparin per ml, and reinfused into the transplant recipient. During the in vitr culture, the cells expand approximately 10 fold so that 2-4X10 cells are returned to the animal. Initially, cells were analyzed after in vitro incubation for evidence of gene transfer and expression. DNA was recovered and subjected to analysis by the polymerase chain reaction methodology using primers (MDR Primer 7, which has the sequence 5'-GCCCACATCATCATGATC-3' and MDR Primer 8, which has the sequence 5'-GTCTCCTACTTTAGTGCT-3' ) specific for the human mdrl coding sequences. Based on comparison to signal intensity obtained with a retorviral producer clone containing a single copy of the retroviral genome, we concluded that 10% of the cells had undergone transduction. The Rhodamine efflux assay hereinabove described was performed confirming that, when compared to a mock infected control sample, 10% of the CD34 selected, transduced cells expressed the mdrl gene product. The transplant recipients received daily intravenous fluids, broad spectrum antibiotics, antifungal agents, hyperalimentation solution and blood products as needed to maintain an optimal physiological condition. Daily blood counts and blood chemistries were obtained to monitor recovery. On day 1 following transplantation, granulocyte colony-stimulating factor was given at a dose of 5ug/kg/day by continuous intravenous 3 infusion. When recovery to a leukocyte count of 1,000-3,000/mm occurs (day 14-22), blood samples are obtained for detection of the mdrl gene and its expression. DNA was purified from the total population of blood leukocytes after lysis of the red cells, and isolation of nuclei from leukocytes. This DNA was analyzed by the polymerase chain reaction methodology using the P7 and P8 primers described above. In the first animal transplanted, approximately 1% of the cells contained the retroviral genome whereas in the second animal 8% of the cells contained the transferred sequences. It is to be understood, however, that the scope of the present invention is nc. to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims. PATAP859 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: McDonagh, Kevin T. Nienhuis, Arthur Tolstoshev, Paul (ii) TITLE OF INVENTION: IMPROVED EXPRESSION OF HUMAN MULTIDRUG RESISTANCE GENES AND IMPROVED SELECTION OF CELLS TRANSDUCED WITH SUCH GENES (iii) NUMBER OF SEQUENCES: 18 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi & Stewart (B) STREET: 6 Becker Farm Road (C) CITY: Roseland (D) STATE: New Jersey (E) COUNTRY: USA (F) ZIP: 07068 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5 inch diskette (B) COMPUTER: IBM PS/2 (C) OPERATING SYSTEM: PC-DOS (D) SOFTWARE: DW4.V2 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: 07/887,712 (B) FILING DATE: 22-MAY-1992 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CAGGTATGC 9 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: ACATTTTTCC TTCAGG 16 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 50 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AGTGAACTCT GGTTAACTCC ACTCGAGCAC AGATCTGGAC ATCGATACTC 50 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: : TCTGTACTGG TCTATACGGA TAATAATGTC 30 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 CTAATTACTT CCATAACCAC TGTTTTAACC 30 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GTAAAAAGGA AGTTCCAAAG TGTAAACCGT 30 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GGAAGACATG ACCAGATATG CCTATTATTA CAG 33 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: "~ 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION; DNA primer ( i) SEQUENCE DESCRIPTION: SEQ ID NO:8: CTGTAATAAT AGGCATATCT GGTCATGTCT TCC 33 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION; DNA primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: CTCTAAGATT AATGAAGGTA TTGGTGACAA AATTG 35 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: CAATTTTGTC ACCAATACCT TCATTAATCT TAGAG 35 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATCGCGGATC CATGGTGGTG GGAACTTTGG C 31 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 12: CATCCGGAAT TCAGCTGACA GTCCAAGAAC AGGACTGATC 40 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: ATCGCGGATC CGGAATTATT TCTTTTATTA CATTTTTCCT TCAAGGTTTC ACATTTGG 5 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: CTCAAAGAGT TTCTGTATGG TACC 24 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GCCCACATCA TCATGATC 18 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: DNA primer (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GTCTCCTACT TTAGTGCT 18 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 53 base pairs, having 4 unpaired bases at the 5' end, and 2 unpai bases at 3' end. (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Plasmid DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: AATTCGCGGC CGCTACGTAG TCGACGGATC CCTCGAGAAG CTTGGGCCCA T GCGCCG GCGATGCATC AGCTGCCTAG GGAGCTCTTC GAACCCGGGT AGC 53 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4669 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: singular (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: Genomic DNA (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Claims: WHAT IS CLAIMED IS: 1. Human mdrl DNA or RNA which encodes p-glycoprotein or an analogue or fragment of such DNA or RNA which encodes an iso-for of p-glycoprotein which confers multidrug resistance, said DNA o RNA including at least one splice site, wherein at least one bas in the splice site has been changed to a different base which thereby inactivates the splice site. 2. The DNA or RNA of Claim 1 wherein said DNA or RNA is a DNA or RNA sequence for a human mdrl gene which encodes p-glycoprotein wherein at least one base in a splice site of sai DNA encoding p-glycoprotein is changed. 3. The DNA sequence of Claim 2 wherein said at least one base is in a splice donor site. 4. The DNA sequence of Claim 2 wherein said at least one base is in a splice acceptor site. 5. The DNA sequence of Claim 2 wherein at least one base in a splice donor site is changed and at least one base in a splice acceptor site is changed. 6. The DNA sequence of Claim 2 wherein said at least one base is in a splice donor site, and is at least one of guanine or thymine contained in said splice donor site, and wherein said guanine and thymine are adjacent. 7. The DNA sequence of Claim 2 wherein said at least one base is in a splice acceptor site, and is at least one of adenine or guanine contained in said splice acceptor site, and wherein said adenine and guanine are adjacent. 8. The DNA sequence of Claim 2 wherein said at least one base in a splice site is changed such tr t a codon encoding an amino acid is changed to a different code:, encoding the same amino acid. 9. The DNA sequence of Claim 8 wherein codon 139 is changed from AGG to AGA. 10. The DNA sequence of Claim 8 wherein codon 733 is changed from CAG to CAA. 11. The DNA sequence of Claim 8 wherein codon 139 is changed from AGG to AGA and codon 733 is changed from CAG to CAA. 12. DNA encoding a protein which provides for multidrug resistance wherein said DNA includes the following sequence: CAGGTATGC wherein at least one base is changed to a different base. 13. The DNA of Claim 12 wherein at least one base of the GT doublet is changed. 14. DNA encoding a protein which provides for multidrug resistance wherein said DNA includes the following sequence: ACATTTTTCCTTCAGG wherein at least one base is changed to a different base. 15. The DNA of Claim 14 wherein at least one base of the AG doublet is changed. 16. DNA encoding a protein which provides for multidrug resistance wherein said DNA includes a first sequence: CAGGTATGC, and a second sequence: ACATTTTTCCTTCAGG, wherein at least one base of said first sequence is changed, and at least one base of said second sequence is changed. 17. The DNA of. Claim 16 wherein at least one base of the GT doublet of the first sequence is changed and at least one base o the AG doublet of the second sequence is changed. 18. The DNA sequence of Claim 2 wherein said DNA sequence is further mutated such that a portion of the 5' untranslated regio of the DNA has been removed. 19. The DNA sequence of Claim 2 where said DNA sequence is further mutated such that a portion of the 3' untranslated regio of the DNA has been removed. 20. The DNA sequence of Claim 2 wherein said DNA sequence is further mutated such that a portion of the 5' untranslated regio of the DNA and a portion of the 3' untranslated region of the DN have been removed. 21. An expression vehicle including the DNA or RNA of Claim 1. 22. The expression vehicle of Claim 21 wherein the expression vehicle is a retroviral vector. 23. Cells genetically engineered with the retroviral vector of Claim 22. 24. A method of identifying cells which overexpress the human mdrl gene in a cell population that has been transduced with an expression vehicle including a human mdrl gene, comprising: contacting said cell population with a staining material; and identifying cells which overexpress the human mdrl gene based on differentiation in color among the cells of said cell population. 25. The method of Claim 24 wherein said staining material is a fluorescent dye. 26. The method of Claim 25 wherein said fluorescent dye is rhodamine 123. 27. Primate cells genetically engineered with DNA or RNA encoding a protein which provides multidrug resistance. 28. The cells of Claim 27 wherein said primate cells are human cells. 29. The cells of Claim 28 wherein said human cells are bone marrow cells. 30. The cells of Claim 28 wherein said human cells are hematopoietic progenitor cells. 31. The cells of Claim 28 wherein the cells are repopulating hematopoietic stem cells.

Inventors: MCDONAGH KEVIN T, NIENHUIS ARTHUR, TOLSTOSHEV PAUL, MCDONAGH, KEVIN, T., NIENHUIS, ARTHUR, TOLSTOSHEV, PAUL
Applicants: GENETIC THERAPY INC, US HEALTH, GENETIC THERAPY, INC., THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE
Application year: 1993
Main classification: C12N5
IPC codes: A61K38, A61K48, C07K14, C12N5, C12N15, G01N33